This “Hepatic encephalopathy - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hepatic encephalopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Hepatic encephalopathy is a decline in brain function that occurs as a result of severe liver disease. Hepatic encephalopathy can be acute (short-term) or chronic (long-term). Symptoms of hepatic encephalopathy differ depending on the underlying cause of the liver damage. There is no specific test used to diagnose hepatic Encephalopathy. A Hepatic Encephalopathy diagnosis is based on a combination of three things: medical history, symptoms, and a thorough clinical exam. Depending on the cause the treatment is aimed at lowering the level of ammonia and other toxins in your blood.
"Hepatic encephalopathy - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatic encephalopathy pipeline landscape is provided which includes the disease overview and Hepatic encephalopathy treatment guidelines. The assessment part of the report embraces, in depth Hepatic encephalopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatic encephalopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Hepatic encephalopathy R&D. The therapies under development are focused on novel approaches to treat/improve Hepatic encephalopathy.
This segment of the Hepatic encephalopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
MNK-6105: Mallinckrodt
MNK-6105 has a novel mechanism of action that may help in eliminating excess ammonia in the bloodstream by excretion through the kidneys. An intravenous form of MNK-6105 is being studied in hospitalized patients with acute hepatic encephalopathy in phase III stage of development.
RBX7455: Rebiotix Inc.
RBX7455 is an oral microbiota-based formulation under the MRT drug platform. The drug is being evaluated in phase II clinical trials for the treatment of patients with Hepatic Encephalopathy.
There are approx. 10+ key companies which are developing the therapies for Hepatic encephalopathy. The companies which have their Hepatic encephalopathy drug candidates in the most advanced stage, i.e. phase III include, Mallinckrodt.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatic encephalopathy therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatic encephalopathy drugs.
Geography Covered
- Global coverage
Hepatic encephalopathy Understanding
Hepatic encephalopathy: Overview
Hepatic encephalopathy is a decline in brain function that occurs as a result of severe liver disease. Hepatic encephalopathy can be acute (short-term) or chronic (long-term). Symptoms of hepatic encephalopathy differ depending on the underlying cause of the liver damage. There is no specific test used to diagnose hepatic Encephalopathy. A Hepatic Encephalopathy diagnosis is based on a combination of three things: medical history, symptoms, and a thorough clinical exam. Depending on the cause the treatment is aimed at lowering the level of ammonia and other toxins in your blood.
"Hepatic encephalopathy - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatic encephalopathy pipeline landscape is provided which includes the disease overview and Hepatic encephalopathy treatment guidelines. The assessment part of the report embraces, in depth Hepatic encephalopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatic encephalopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Hepatic encephalopathy R&D. The therapies under development are focused on novel approaches to treat/improve Hepatic encephalopathy.
Hepatic encephalopathy Emerging Drugs Chapters
This segment of the Hepatic encephalopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hepatic encephalopathy Emerging Drugs
MNK-6105: Mallinckrodt
MNK-6105 has a novel mechanism of action that may help in eliminating excess ammonia in the bloodstream by excretion through the kidneys. An intravenous form of MNK-6105 is being studied in hospitalized patients with acute hepatic encephalopathy in phase III stage of development.
RBX7455: Rebiotix Inc.
RBX7455 is an oral microbiota-based formulation under the MRT drug platform. The drug is being evaluated in phase II clinical trials for the treatment of patients with Hepatic Encephalopathy.
Hepatic encephalopathy: Therapeutic Assessment
This segment of the report provides insights about the different Hepatic encephalopathy drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Hepatic encephalopathy
There are approx. 10+ key companies which are developing the therapies for Hepatic encephalopathy. The companies which have their Hepatic encephalopathy drug candidates in the most advanced stage, i.e. phase III include, Mallinckrodt.
Phases
This report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Hepatic encephalopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Subcutaneous
- Intravenous
- Intramuscular
- Molecule Type
Products have been categorized under various Molecule types such as
- Bispecific Antibody
- Peptides
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Hepatic encephalopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatic encephalopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatic encephalopathy drugs.
Hepatic encephalopathy Report Insights
- Hepatic encephalopathy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Hepatic encephalopathy Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Hepatic encephalopathy drugs?
- How many Hepatic encephalopathy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatic encephalopathy?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hepatic encephalopathy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hepatic encephalopathy and their status?
- What are the key designations that have been granted to the emerging drugs?
Table of Contents
IntroductionExecutive Summary
Hepatic encephalopathy: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Hepatic encephalopathy - Analytical Perspective
In-depth Commercial Assessment
- Hepatic encephalopathy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Hepatic encephalopathy Collaboration Deals
- Company-Company Collaborations (Licensing/Partnering) Analysis
- Company-University Collaborations (Licensing/Partnering) Analysis
Late Stage Products (Phase III)
- Comparative Analysis
MNK-6105: Mallinckrodt
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
RBX7455: Rebiotix Inc.
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Preclinical Stage Products
- Comparative Analysis
Neur-001: Neuractas therapeutics
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Hepatic encephalopathy Key Companies
Hepatic encephalopathy Key Products
Hepatic encephalopathy- Unmet Needs
Hepatic encephalopathy- Market Drivers and Barriers
Hepatic encephalopathy- Future Perspectives and Conclusion
Hepatic encephalopathy Analyst Views
Hepatic encephalopathy Key Companies
AppendixList of Tables
Table 1 Total Products for Hepatic encephalopathy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Hepatic encephalopathy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Surrozen
- Axcella health
- Versantis AG
- Rebiotix Inc.
- Mallinckrodt
- Sigyn Therapeutics
- Kaleido Biosciences, Inc.
- Neuractas Therapeutics
